179 related articles for article (PubMed ID: 31410730)
1. Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.
Wang Y; Zhang Y
Clin Transl Oncol; 2020 Jun; 22(6):835-843. PubMed ID: 31410730
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of the IL-6 family of cytokines predict prognosis in renal cell carcinoma (RCC).
Gudbrandsdottir G; Aarstad HH; Bostad L; Hjelle KM; Aarstad HJ; Bruserud Ø; Tvedt THA; Beisland C
Cancer Immunol Immunother; 2021 Jan; 70(1):19-30. PubMed ID: 32621022
[TBL] [Abstract][Full Text] [Related]
3. Tumour necrosis factor-alpha, interleukin-1 beta and interleukin-6 in patients with renal cell carcinoma.
Dosquet C; Schaetz A; Faucher C; Lepage E; Wautier JL; Richard F; Cabane J
Eur J Cancer; 1994; 30A(2):162-7. PubMed ID: 8155390
[TBL] [Abstract][Full Text] [Related]
4. Resistin and interleukin 6 as predictive factors for recurrence and long-term prognosis in renal cell cancer.
Kallio J; Hämäläinen M; Luukkaala T; Moilanen E; Tammela TL; Kellokumpu-Lehtinen PL
Urol Oncol; 2017 Sep; 35(9):544.e25-544.e31. PubMed ID: 28572026
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
[TBL] [Abstract][Full Text] [Related]
6. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay JY; Negrier S; Combaret V; Attali S; Goillot E; Merrouche Y; Mercatello A; Ravault A; Tourani JM; Moskovtchenko JF
Cancer Res; 1992 Jun; 52(12):3317-22. PubMed ID: 1596890
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein is a predictor of prognosis in renal cell carcinoma patients receiving tyrosine kinase inhibitors: A meta-analysis.
Wang Z; Peng S; Wang A; Xie H; Guo L; Jiang N; Niu Y
Clin Chim Acta; 2017 Dec; 475():178-187. PubMed ID: 29080691
[TBL] [Abstract][Full Text] [Related]
8. The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis.
Shen H; Liu Q; Li M; Yang P
Clin Invest Med; 2017 Apr; 40(2):E40-E48. PubMed ID: 28447576
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and clinicopathological significance of PD-L1 in patients with renal cell carcinoma: a meta-analysis based on 1863 individuals.
Wang Z; Peng S; Xie H; Guo L; Cai Q; Shang Z; Jiang N; Niu Y
Clin Exp Med; 2018 May; 18(2):165-175. PubMed ID: 29362922
[TBL] [Abstract][Full Text] [Related]
10. Sarcomatoid renal cell carcinoma: biologic behavior, prognosis, and response to combined surgical resection and immunotherapy.
Cangiano T; Liao J; Naitoh J; Dorey F; Figlin R; Belldegrun A
J Clin Oncol; 1999 Feb; 17(2):523-8. PubMed ID: 10080595
[TBL] [Abstract][Full Text] [Related]
11. Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma.
Pedersen MM; Donskov F; Pedersen L; Zhang ZF; Nørgaard M
Acta Oncol; 2020 Jan; 59(1):13-19. PubMed ID: 31448981
[No Abstract] [Full Text] [Related]
12. Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma: a meta- analysis of observational studies.
Li B; Huang D; Zheng H; Cai Q; Guo Z; Wang S
Int Braz J Urol; 2020; 46(2):158-168. PubMed ID: 31961621
[TBL] [Abstract][Full Text] [Related]
13. Control of hepatic parameters in renal cell carcinoma (RCC) by interleukin-6 (IL-6)?
Wechsel HW; Feil G; Lahme S; Zumbragel A; Petri E; Bichler KH
Anticancer Res; 1999; 19(4A):2577-81. PubMed ID: 10470198
[TBL] [Abstract][Full Text] [Related]
14. Increased preoperative levels of plasma fibrinogen and D dimer in patients with renal cell carcinoma is associated with poor survival and adverse tumor characteristics.
Erdem S; Amasyali AS; Aytac O; Onem K; Issever H; Sanli O
Urol Oncol; 2014 Oct; 32(7):1031-40. PubMed ID: 25027687
[TBL] [Abstract][Full Text] [Related]
15. High YKL-40 is associated with poor survival in patients with renal cell carcinoma: a novel independent prognostic marker.
Väänänen T; Kallio J; Vuolteenaho K; Ojala A; Luukkaala T; Hämäläinen M; Tammela T; Kellokumpu-Lehtinen PL; Moilanen E
Scand J Urol; 2017 Oct; 51(5):367-372. PubMed ID: 28644702
[TBL] [Abstract][Full Text] [Related]
16. Cancer stem cell markers predict a poor prognosis in renal cell carcinoma: a meta-analysis.
Cheng B; Yang G; Jiang R; Cheng Y; Yang H; Pei L; Qiu X
Oncotarget; 2016 Oct; 7(40):65862-65875. PubMed ID: 27588469
[TBL] [Abstract][Full Text] [Related]
17. The prognostic value of C-reactive protein in renal cell carcinoma: a systematic review and meta-analysis.
Hu Q; Gou Y; Sun C; Ding W; Xu K; Gu B; Xia G; Ding Q
Urol Oncol; 2014 Jan; 32(1):50.e1-8. PubMed ID: 24239465
[TBL] [Abstract][Full Text] [Related]
18. Interleukin 6 induces cell proliferation of clear cell renal cell carcinoma by suppressing hepaCAM via the STAT3-dependent up-regulation of DNMT1 or DNMT3b.
Quan Z; He Y; Luo C; Xia Y; Zhao Y; Liu N; Wu X
Cell Signal; 2017 Apr; 32():48-58. PubMed ID: 28093267
[TBL] [Abstract][Full Text] [Related]
19. Pretherapeutic Plasma Fibrinogen Level is an Independent Survival Predictor in Renal Cell Carcinoma.
Sasaki T; Onishi T
Oncol Res Treat; 2015; 38(7-8):374-8. PubMed ID: 26278582
[TBL] [Abstract][Full Text] [Related]
20. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival.
Walther MM; Johnson B; Culley D; Shah R; Weber J; Venzon D; Yang JC; Linehan WM; Rosenberg SA
J Urol; 1998 Mar; 159(3):718-22. PubMed ID: 9474133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
